Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act ---- Beginning January 1, 2025, providers can ...

Drug–ligand conjugates and ligand-anchored carrier systems encapsulating drug/gene have been developed and well characterized for the purpose of targeted breast cancer therapy. Liposomes serve ...

therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.

Operator: Good day, and welcome to the Third Quarter 2024 Pacira Biosciences Inc. Earnings Conference Call. At this time, all ...

Pacira ended the third quarter of 2024 with cash, cash equivalents and available-for-sale investments (“cash”) of $453.8 million. Cash provided by operations was $53.9 million in the third quarter of ...

Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long ... a novel locally administered gene therapy with the potential to treat large ...

This article highlights several inspiring men and women working across academia and industry who are breaking barriers and ...

Liposomal daunorubicin and cytarabine (CPX ... Data from this new study suggest that tailoring induction therapy for acute myeloid leukemia (AML) based on cytarabine pharmacogenomic 10–single ...

The nanomedicine is emerging as a promising strategy to achieve maximal anti-tumor effect in cancer therapy. In this review ... Notch receptors also triggers the upregulation of the δNp63 gene in HNC, ...

Application of these bio-inspired drug delivery systems include photodynamic therapy ... Liposome functionalization with copper-free “click chemistry”. Journal of Controlled Release, 202, 14-20.